Oral Biol Res.
2024 Jun;48(2):45-51. 10.21851/obr.48.02.202406.45.
Surgical treatment of medication-related osteonecrosis of the jaw in patients with autoimmune diseases
- Affiliations
-
- 1Associate Professor, Department of Dentistry, Institute of Medical Science, Gyeongsang National University School of Medicine, Jinju, Republic of Korea
- 2Clinical Instructor, Department of Dentistry, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea
- KMID: 2557490
- DOI: http://doi.org/10.21851/obr.48.02.202406.45
Abstract
- This retrospective, single-center study compares the factors influencing the surgical outcomes of medication-related osteonecrosis of the jaw (MRONJ) in patients with and without autoimmune diseases (AIDs). The total surgical success rate was 92% during the mean 2-year follow-up period, and treatment failure was observed in 8% of all patients without AID and 12% of patients with AIDs. Bisphosphonate duration and administration route (intravenous) were found to be risk factors of MRONJ. A careful treatment plan should be developed with a multidisciplinary team including a rheumatologist and a maxillofacial surgeon to avoid the use of drugs that may adversely affect treatment results when MRONJ occurs in patients with AIDs.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis
- Medication-Related Osteonecrosis of the Jaws: A Literature Review
- Polydeoxyribonucleotide, as a Novel Approach for the Management of Medication-Related Osteonecrosis of the Jaw: A Preliminary Observational Study
- Clinical feature and treatment of bisphosphonate-related osteonecrosis of jaw about oral bisphosphonate administrated patients: case reports
- Bisphosphonate-Related Osteonecrosis in a Patient with Florid Cemento-Osseous Dysplasia
